STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)--Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptor (GPCR) driven immuno-resistance, today announces the publication of three international PCT patent applications..

法国斯特拉斯堡和蒙特利尔与波士顿--（商业新闻短讯）--Domain Therapeutics（“Domain”或“the Company”），一家全球临床阶段的生物制药公司，开发针对G蛋白偶联受体（GPCR）驱动的免疫抗性的免疫肿瘤学创新候选药物，今天宣布发布三项国际PCT专利申请。。

These patents will significantly strengthen the Company’s intellectual property protection for its series of tumor-infiltrating regulatory T cells (Tregs) depleting antibody-dependent cell-mediated cytotoxicity/ phagocytosis (ADCC/ADCP) anti-CCR8 antibodies, including DT-7012, a novel drug candidate with best-in-class potential compared to other clinical-stage CCR8 antibodies.

这些专利将大大加强该公司对其一系列肿瘤浸润调节性T细胞（Tregs）的知识产权保护，这些T细胞消耗抗体依赖性细胞介导的细胞毒性/吞噬作用（ADCC/ADCP）抗CCR8抗体，包括DT-7012，一种与其他临床阶段CCR8抗体相比具有同类最佳潜力的新型候选药物。

Currently in the pre-IND stage of development, DT-7012 is set to commence Phase I clinical trials in early 2025..

目前，DT-7012处于IND前期开发阶段，计划于2025年初开始I期临床试验。。

Stephan Schann, Chief Scientific Officer of Domain Therapeutics, said: “These three new patents are pivotal to our strategy, enhancing our robust patent estate and expanding our reach across diverse market opportunities. They underscore the broad international application of our Treg depleting ADCC/ADCP anti-CCR8 antibodies, particularly for our lead anti-CCR8 candidate DT-7012.

Domain Therapeutics首席科学官斯蒂芬·沙恩（Stephan Schann）表示：“这三项新专利对我们的战略至关重要，增强了我们强大的专利资产，并扩大了我们在各种市场机会中的影响力。它们突显了我们的Treg消耗型ADCC/ADCP抗CCR8抗体的广泛国际应用，特别是对于我们的主要抗CCR8候选DT-7012。

They also reinforce Domain’s position as an industry leader in GPCR-mediated immunotherapies. Notably, this timely publication of PCT patent applications aligns with our accelerated and broadened research and development efforts in immuno-oncology.”.

它们还巩固了Domain在GPCR介导的免疫疗法中作为行业领导者的地位。值得注意的是，PCT专利申请的及时公布与我们在免疫肿瘤学方面加速和扩大的研究和开发工作相一致。”。

CCR8 is a GPCR target specifically expressed by tumor infiltrating Tregs, major immunosuppressive cells responsible for the failure of several therapeutics in the clinic, which makes this target highly strategic for the development of efficient novel immunotherapies.

CCR8是由肿瘤浸润性Tregs特异性表达的GPCR靶标，Tregs是导致临床上几种治疗失败的主要免疫抑制细胞，这使得该靶标对于开发有效的新型免疫疗法具有高度战略性。